Moreover, Fong et al. [91] reported that subcutaneous administration of recombinant Flt3L expands circulating DCs (HLADR+CD3−CD14−CD19−CD56−) in carcinoembryonic antigen (CEA)+ cancer patients. This evidence concerns the gene FLT3LG and cancer.